Published by Oliver Haill on 11th May 2017
(ShareCast News) - After receiving an unfavourable verdict from US drug regulators, Hikma Pharamceuticals and Vectura felt there was a "low likelihood" that their generic version of asthma treatment Advair would be approved this year.
URL: http://www.digitallook.com/dl/news/story/25920815/...